Seventure Partners

Anybuddy is a leading sports booking marketplace in France, specializing in racket sports. The company has developed a sports application that allows users to find players and book pitches for football and tennis matches. Its platform provides access to numerous clubs, facilitating reservations and payments without requiring a license or subscription. Users can access a wide selection of quality tennis courts and various playing surfaces, all at competitive prices. Anybuddy aims to simplify the process of booking sports facilities and encourage more participation in physical activities.

Syroco is a scientific and technical laboratory based in Marseille, France, established in 2019. The company focuses on enhancing efficiency in the energy and transportation sectors through innovative solutions. Syroco specializes in developing a speed craft with the aim of breaking sailing speed records and engages in projects that involve designing and building advanced engineering systems. The team comprises diverse professionals, including a kitesurfer, a two-time world sailing speed record holder, digital entrepreneurs, and a naval architect. Syroco's approach includes tackling "moonshot challenges," which are ambitious technological endeavors. Additionally, the company employs data and artificial intelligence to create modeling software that supports the energy transition in maritime transportation, facilitating the optimization of operational and energy efficiency for both on-board and shore applications.

Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

Nexess SAS is a company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Founded in 2006 and based in Mougins, France, with an additional office in Paris, the company offers a range of products including NexLink, a software platform designed to enhance security and productivity. Its offerings also encompass various identification products such as personal security badges, RFID tags, and mobile devices, along with smart camera systems that provide autonomous image analysis and real-time data transmission. Nexess's solutions are utilized for applications like hazardous product traceability, managing smart secured cabinets, site localization, and monitoring access to hazardous zones. By integrating technologies such as RFID, Nexess supports major digital transformation projects, enhancing clients' performance in productivity, quality, and security.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Mediarithmics is a cloud-based data marketing platform headquartered in Fontenay-sous-Bois, France, that was established in 2011. It provides a solution for brands to manage retargeting campaigns across multiple devices and enables agencies to handle clients' real-time bidding (RTB) and email campaigns through a unified tool. The platform functions as a next-generation Customer Data Platform (CDP) that encompasses all aspects of Data Management Platforms (DMP) and CDPs. It facilitates the creation of Data Alliances, ensuring data security and compliance with regulations. Mediarithmics' technology allows for the collection of comprehensive customer and prospect data, enabling real-time segmentation and activation of multi-channel marketing campaigns. Clients can also customize the platform by incorporating their own algorithms to enhance marketing personalization and data monetization strategies. Overall, Mediarithmics aims to improve consumer engagement and drive growth through data-driven outreach strategies.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

HARDLOOP SARL is an online retailer based in Paris, France, specializing in sports products and adventure gear. Founded in 2014, the company offers a wide range of items, including shoes, gloves, bottles, and various accessories tailored for outdoor activities such as hiking, trail running, skiing, climbing, and swimming. By providing a diverse selection from international brands, HARDLOOP aims to equip sports enthusiasts with the necessary gear for their adventures. The platform facilitates easy access to quality sports apparel and accessories, catering to the needs of active individuals seeking to enhance their outdoor experiences.

SportEasy is a user-friendly web and mobile application designed to assist amateur sports teams in managing their activities. Launched in France in 2011, the platform enables coaches to organize games and practices, communicate effectively with players, and analyze team statistics. It also includes social features that allow players to engage with teammates through activities like voting for the player of the game and sharing photos. Available in both French and English, SportEasy aims to streamline the administrative tasks associated with sports management, allowing coaches, managers, and volunteers to focus more on the field and less on paperwork. While the basic features of the application are free, premium plans for teams and clubs have been introduced to provide additional functionality.

Expensya SAS, founded in 2014 and based in Paris, France, specializes in expense management software solutions. Its flagship product, the Expensya application, is a web and mobile platform that automates the management of professional expense reports from receipt processing to archiving. The software incorporates advanced technologies such as Cloud computing, Artificial Intelligence, and Big Data to enhance efficiency in expense management. It offers features including expense tracking, data export, accountant integration, approval workflows, and mileage management, while also supporting local accounting regulations in approximately fifty countries. The platform is available in eight languages, catering to the diverse needs of businesses and simplifying the claims process.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

HARDLOOP SARL is an online retailer based in Paris, France, specializing in sports products and adventure gear. Founded in 2014, the company offers a wide range of items, including shoes, gloves, bottles, and various accessories tailored for outdoor activities such as hiking, trail running, skiing, climbing, and swimming. By providing a diverse selection from international brands, HARDLOOP aims to equip sports enthusiasts with the necessary gear for their adventures. The platform facilitates easy access to quality sports apparel and accessories, catering to the needs of active individuals seeking to enhance their outdoor experiences.

TIBOT Technologies SAS, established in 2016 and based in Cesson-Sévigné, France, specializes in designing and developing robotic solutions for poultry farming. The company focuses on enhancing the daily operations of poultry farmers through innovative technology. Its flagship products include Spoutnic, an assistant robot, and Spoutnic NAV, which autonomously scrapes, drinks, and feeds poultry. These robots are designed to improve animal welfare, increase hatching rates, and optimize working conditions for farmers, ultimately enhancing profitability in poultry operations. TIBOT Technologies aims to facilitate the poultry farming process by integrating automation and efficiency into traditional farming practices.

Expensya SAS, founded in 2014 and based in Paris, France, specializes in expense management software solutions. Its flagship product, the Expensya application, is a web and mobile platform that automates the management of professional expense reports from receipt processing to archiving. The software incorporates advanced technologies such as Cloud computing, Artificial Intelligence, and Big Data to enhance efficiency in expense management. It offers features including expense tracking, data export, accountant integration, approval workflows, and mileage management, while also supporting local accounting regulations in approximately fifty countries. The platform is available in eight languages, catering to the diverse needs of businesses and simplifying the claims process.

Presto Engineering, Inc. is a provider of outsourced development operations tailored for semiconductor and Internet of Things (IoT) device companies. Established in 2006 and headquartered in San Jose, California, the company delivers a comprehensive suite of services, including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, and various testing and analysis services. These services encompass product engineering, debugging, reliability testing, and failure analysis, aimed at enhancing product performance and minimizing risk. Presto Engineering also specializes in wafer fabrication, backend packaging, and supply chain solutions, supporting clients in the medical, automotive, industrial, and communication sectors. With additional offices in France, Thailand, and Taiwan, the company is positioned to facilitate rapid product development and help clients accelerate their time-to-market.

Launchmetrics is a marketing and analytics platform that specializes in serving the fashion, luxury, and beauty industries. Founded in 2006 and headquartered in New York, with additional operations in Paris, the company offers a suite of products designed to enhance brand performance and streamline marketing processes. Its offerings include Samples, Events, Contacts, Discover, and Influencers by Launchmetrics, which collectively assist brands in planning product launches and improving media performance. The company has established itself as a trusted technology provider, working with over 1,000 clients, including prominent names like Dior, Fendi, and NET-A-PORTER, as well as partners such as the British Fashion Council and Google. With a presence in eight markets and support in five languages, Launchmetrics aims to empower brands to create impactful and measurable consumer experiences, adapting to the rapidly changing digital landscape. The company was originally known as Fashion GPS, Inc. before rebranding in January 2016.

MDoloris Medical Systems SAS is a French company founded in 2010, specializing in the development and manufacturing of medical devices aimed at monitoring and alleviating patient pain. The company’s flagship product, the Analgesia Nociception Index (ANI) monitor, measures the activity of the autonomic nervous system to provide insights into patient pain levels, particularly for those who are non-communicative, such as those under general anesthesia or in intensive care. Additional offerings include ANI sensors and PhysioDoloris monitors, which are utilized across various healthcare settings, including surgical wards, ICUs, obstetrics, and neonatal care units. MDoloris also provides after-sales service to support its products. The company focuses on improving patient outcomes by enabling clinicians to better manage analgesic administration and assess patients’ comfort levels.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Intento Design SA specializes in developing software solutions that enhance the design and migration processes of analog and mixed-signal integrated circuits. Founded in 2015 and headquartered in Paris, France, the company offers ID-Xplore, a tool that automates circuit sizing and streamlines the analog design process, significantly reducing latency. In addition to its software, Intento Design provides services such as methodology adoption, design collaboration, and technology migration. Their innovative approach aims to address productivity challenges faced by electrical designers, particularly in industries like consumer electronics, the Internet of Things, big data, military, and medical markets. The company's work is rooted in research conducted at the Laboratoire d’Informatique de Paris 6, leading to a robust portfolio of intellectual property that supports its mission to simplify and accelerate the analog design cycle for complex systems on chip (SoCs) used in various connected applications.

TargEDys is a company based in Rouen, France, that specializes in developing innovative treatments for eating disorders such as hyperphagia and anorexia. Established in 2011, TargEDys focuses on harnessing hormone mimetic proteins associated with the gut microbiota to regulate appetite. Their approach involves utilizing natural bacterial proteins found in the gut microbiome to modulate eating behavior, helping to control appetite in overweight individuals and restore normal eating patterns in elderly or cachexic patients. Through its research and development efforts, TargEDys aims to provide effective solutions for those struggling with metabolic diseases related to appetite regulation.

Business Table is the leader in corporate dining and corporate events, with more than 30,000 service providers, including 15,000 restaurants, 1,500 caterers and 14,000 hotels and locations across France. This innovative solution launched in 2012 allows companies, from large groups to SMEs, to streamline the management of meal costs through a simple, innovative and efficient booking, ordering and invoicing tool. To expand its service offering, Business Table has partnered with American Express, Concur, Edenred and AirPlus

Botfuel, established in 2016 and headquartered in Paris, France, specializes in a web-based platform and SDK for creating and deploying chatbots. It empowers individuals and businesses to engage with customers on popular messaging channels, providing automated, personalized support and enhancing brand engagement. The company's AI-driven technology enables the development of modular, scalable chatbots, aiming to improve customer support and drive sales.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

TargEDys is a company based in Rouen, France, that specializes in developing innovative treatments for eating disorders such as hyperphagia and anorexia. Established in 2011, TargEDys focuses on harnessing hormone mimetic proteins associated with the gut microbiota to regulate appetite. Their approach involves utilizing natural bacterial proteins found in the gut microbiome to modulate eating behavior, helping to control appetite in overweight individuals and restore normal eating patterns in elderly or cachexic patients. Through its research and development efforts, TargEDys aims to provide effective solutions for those struggling with metabolic diseases related to appetite regulation.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

MilliDrop Instruments SAS specializes in the design and development of cell culture machines utilizing millifluidics technology for bacteriological research and diagnostic applications. Founded in 2015 and based in Paris, France, the company offers advanced in vitro diagnostic machines that facilitate the incubation, analysis, and manipulation of samples, with volumes ranging from approximately 100 nanolitres to a few picolitres. Their innovative MilliDrop DIV instruments enable users to identify infectious agents and determine the appropriate antibiotic doses needed to effectively combat them, thereby minimizing therapeutic failures linked to improper antibiotic selection or excessive dosages. Additionally, MilliDrop's analyzers allow for the simultaneous study and cultivation of various cell cultures, as well as the sorting of phenotypes of interest and conducting serial dilutions, supporting microbiologists in their efforts to screen microbes for antimicrobial susceptibility testing.

HorseCom SAS, established in 2015 and based in Caen, France, specializes in Bluetooth audio headset technology tailored for horses and riders. The company's innovative products aim to enhance the well-being, performance, and connection between horses and their riders. HorseCom has developed a patented wearable device that diffuses music to both the horse and rider, fostering stronger bonds and improved synchronization during training and competition. This technology includes a Bluetooth earpiece for the rider, a cap with a Bluetooth receiver, earphones designed for equine ears, and a mobile application. By focusing on the welfare of horses, HorseCom's solutions promote recovery and reduce stress in anxiety-inducing situations, ultimately contributing to better training outcomes in equestrian sports.

Intento Design SA specializes in developing software solutions that enhance the design and migration processes of analog and mixed-signal integrated circuits. Founded in 2015 and headquartered in Paris, France, the company offers ID-Xplore, a tool that automates circuit sizing and streamlines the analog design process, significantly reducing latency. In addition to its software, Intento Design provides services such as methodology adoption, design collaboration, and technology migration. Their innovative approach aims to address productivity challenges faced by electrical designers, particularly in industries like consumer electronics, the Internet of Things, big data, military, and medical markets. The company's work is rooted in research conducted at the Laboratoire d’Informatique de Paris 6, leading to a robust portfolio of intellectual property that supports its mission to simplify and accelerate the analog design cycle for complex systems on chip (SoCs) used in various connected applications.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

Mailjet is an email service provider founded in France in 2010, specializing in marketing and transactional emails. With a global client base of over 26,000 across 156 countries, Mailjet facilitates the sending of nearly 1 billion emails monthly. The company offers a comprehensive platform that includes analytics tools and APIs, allowing users to efficiently create, send, and optimize their email communications. Mailjet's proprietary technology and consulting services focus on maximizing email deliverability. The platform features innovative options such as A/B testing and campaign comparison to enhance customer engagement. Additionally, their support team provides assistance in multiple languages, including English, French, German, and Spanish, ensuring that clients receive timely help with their inquiries.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Augure is a software company founded in 2002 in Paris, specializing in influencer marketing and public relations solutions. The company offers a platform that assists brands and agencies in managing their communication strategies by bridging the gap between traditional PR and influencer marketing. With over 1,000 clients utilizing the platform daily, Augure enables communication, PR, and public affairs teams to engage with relevant influencers, streamline campaign management, and enhance their media presence on social networks. In addition to its software, Augure provides consulting services through its data services team, helping clients interpret and leverage data to optimize their influencer marketing strategies. The company operates primarily in Europe and Latin America, serving a diverse range of clients, including prominent organizations in the corporate sector.

Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

Open Ocean SAS is a company that specializes in developing a SaaS-based decision-making platform focused on managing offshore infrastructure and marine operations. Founded in 2011 and headquartered in Paris and Brest, the company offers a range of products and services, including the Metocean Analytics solution, which analyzes atmospheric and oceanic conditions, and a detailed report on the tidal energy market in France. Additionally, Open Ocean provides a spectral wave database for Scotland, facilitating the development of marine renewable energy. Its services encompass site data analysis, resource and energy assessment, environmental data for design calculations, and research and development for offshore energy projects. Open Ocean caters to farm developers, operators, and public agencies within the renewable marine energy sector, leveraging a highly qualified team of oceanographers skilled in high-resolution modeling and data analysis.

JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Webinterpret, established in 2007, focuses on making international e-commerce accessible to sellers worldwide. With offices in France, Poland, China, and the USA, the company employs approximately 210 skilled e-commerce specialists who possess in-depth local market knowledge. Webinterpret operates a global marketplace platform designed to help online merchants expand their reach internationally. The platform offers a range of services, including adjustments to shipping costs, currency conversion, product categorization, accurate translations, and international stock management. These services enable online retailers and marketplace sellers to effectively grow their businesses on a global scale and enhance their online sales.

Streamdata.io is a developer of real-time API management software focused on event-driven infrastructure. Founded in 2008 and headquartered in Meylan, France, the company, previously known as Mobile Service SAS, operates as a subsidiary of Axway Software SA. Streamdata.io offers three primary services: Distribute, Journey, and Discover. Distribute enables the consumption and publication of events alongside APIs, transforming traditional request/response models into streams of events. Journey provides consulting services and a platform to assist companies in managing their API lifecycle, while Discover helps organizations catalog their digital assets to design effective APIs. The company has collaborated with various partners, including Xignite and Salesforce, to enhance its offerings. Streamdata.io has received multiple accolades, including the European Data Award in 2016 and recognition as a top startup in France. Additionally, the company contributes to industry standards such as AsynchAPI and OpenAPI, emphasizing its commitment to advancing API technology.

Advanced Accelerator Applications S.A., founded in 2002 and based in Saint Genis Pouilly, France, specializes in the development, production, and commercialization of molecular nuclear medicine products for diagnostic and therapeutic purposes. The company offers a range of products including oxodotreotides, dotatate injections, edotreotide solutions, flurochol, and gluscan, which are used in oncology, cardiology, and neurology. Additionally, it provides innovative solutions like LysaKare for reducing kidney radiation exposure during therapy, DOPAVIEW for rapid tissue accumulation, CARDIOGEN for producing rubidium chloride, NEUROLITE for radiopharmaceutical preparation, LUMARK as a radiopharmaceutical precursor, and LEUKOKIT for leukocyte separation and labeling. The company's theragnostic platform uses radiolabeling to target tumor cells, aiding in diagnosis, monitoring, and staging. Advanced Accelerator Applications operates as a subsidiary of Novartis AG.

Nexess SAS is a company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Founded in 2006 and based in Mougins, France, with an additional office in Paris, the company offers a range of products including NexLink, a software platform designed to enhance security and productivity. Its offerings also encompass various identification products such as personal security badges, RFID tags, and mobile devices, along with smart camera systems that provide autonomous image analysis and real-time data transmission. Nexess's solutions are utilized for applications like hazardous product traceability, managing smart secured cabinets, site localization, and monitoring access to hazardous zones. By integrating technologies such as RFID, Nexess supports major digital transformation projects, enhancing clients' performance in productivity, quality, and security.

Recommerce Group specializes in providing trade-in and remarketing solutions for second-hand mobile phones across Europe. The company focuses on the refurbishment and resale of smartphones, employing innovative proprietary technologies to enhance the lifecycle of these devices. Its services encompass a comprehensive range of solutions, including multi-channel trade-in options, reverse logistics, data erasure, and customer support, along with marketing and e-commerce support. Recommerce Group also offers rental services for smartphones and tablets, catering to diverse clients such as mobile operators, distributors, e-tailers, and manufacturers. With a strong presence in France, Spain, Switzerland, and Poland, the company collaborates with notable retailers and mobile network operators to promote sustainable practices in the electronics market. Founded in 2009 and headquartered in Paris, Recommerce Group is dedicated to giving smartphones a second life while providing affordable access to quality electronics.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Web Geo Services SAS, established in 2009 and headquartered in Montpellier, France, specializes in online mapping and location-based applications. The company focuses on providing location SaaS technology for various sectors, including retail, e-commerce, travel, hospitality, banking, insurance, automotive, and mobility. By leveraging Google Maps, Web Geo Services assists businesses in enhancing customer engagement and driving conversions through digital systems that streamline online checkouts and customer journeys. With a client base of over 400 large companies, it has positioned itself as a leading partner of Google Cloud and the foremost Google Maps partner in Europe, with offices in multiple countries. The company has developed Woosmap, an award-winning platform that enables developers to integrate advanced location intelligence features into mobile applications and websites, thereby offering businesses a competitive edge in their respective markets.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

ProTip SA is a privately held medical device company dedicated to the development of innovative solutions for patients suffering from larynx malfunctions. Its priority focus is to develop a permanent implant for laryngectomized patients. ProTip, based in Strasbourg (Eastern France), was founded in 2004 and has since benefited from strong support from the Alsace region and Oseo, the French public agency for innovation. The company has won several prestigious awards in France. It has established partnerships with a number of academic institutions. The international expansion of the company has recently accelerated due to the ISO certification and CE mark achievement on essential product lines.

LNC Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target the gut microbiota to treat obesity and associated cardiometabolic diseases. The company's pipeline encompasses fundamental research, preclinical studies, and clinical trials, aiming to bring a next-generation approach to these health challenges. Backed by prominent venture capital investors and family offices, LNC Therapeutics has raised €16.5 million to date, including €1.5 million in grants from French BPI and the Aquitaine Region. The company collaborates globally with renowned medical experts to ensure high standards in its drug development process.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Streamdata.io is a developer of real-time API management software focused on event-driven infrastructure. Founded in 2008 and headquartered in Meylan, France, the company, previously known as Mobile Service SAS, operates as a subsidiary of Axway Software SA. Streamdata.io offers three primary services: Distribute, Journey, and Discover. Distribute enables the consumption and publication of events alongside APIs, transforming traditional request/response models into streams of events. Journey provides consulting services and a platform to assist companies in managing their API lifecycle, while Discover helps organizations catalog their digital assets to design effective APIs. The company has collaborated with various partners, including Xignite and Salesforce, to enhance its offerings. Streamdata.io has received multiple accolades, including the European Data Award in 2016 and recognition as a top startup in France. Additionally, the company contributes to industry standards such as AsynchAPI and OpenAPI, emphasizing its commitment to advancing API technology.

Impeto Medical SAS is a privately owned medical device company based in Paris, France, established in 2005. The company specializes in manufacturing and marketing non-invasive devices that assess eccrine sweat gland activity. Its key products include SUDOSCAN+, which detects and monitors peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardiometabolic risks; and SUDOSCAN, which evaluates galvanic skin response to assess the sympathetic nervous system's behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical utilizes patented technology to analyze sudomotor function, enabling healthcare providers to screen large patient populations for early detection of diseases and complications. The company distributes its products through a network of distributors and has subsidiary locations in China and San Diego, California.

Talentsoft, established in 2007, is a leading French software company specializing in cloud-based Talent Management solutions. It offers a comprehensive suite of services, including recruitment, onboarding, performance management, and learning management, all integrated on a single platform. Talentsoft has achieved rapid growth and international success by forming strategic partnerships, maintaining high-caliber teams, and providing an attractive technology solution. With numerous awards and financial backing, the company has expanded its global presence to every continent, serving clients through its network of subsidiaries and affiliates.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Arlettie, originally founded as Espace Max in 1993, is based in Paris, France, and specializes in online retail of luxury fashion apparel and accessories. The company operates as an event organizer for private sales and exclusive shopping events, acting as an intermediary between luxury brands and customers. Through its platform, Arlettie offers a curated selection of high-end fashion, accessories, and lifestyle products from renowned brands, facilitating unique shopping experiences for consumers seeking exclusive items.

EffiCity SAS is an online real estate agency based in Paris, France, established in 2007. The company specializes in providing a range of real estate services, including the buying and selling of properties, as well as property management and valuation. EffiCity utilizes digital platforms to facilitate transactions, making it easier for clients to navigate the real estate market.

QuesCom S.A., founded in 1999 and headquartered in Sophia Antipolis, France, specializes in designing and manufacturing Internet telecommunication systems. The company offers a range of products including business communication management portals, GSM gateways, SIM servers, and mobile call servers. Its technology encompasses VoIP solutions and network management software, catering to both enterprises and service providers. QuesCom collaborates with established industry partners such as Aastra, Alcatel, Avaya, and Cisco to enhance its offerings and maintain a competitive edge in the telecommunications market.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Presto Engineering, Inc. is a provider of outsourced development operations tailored for semiconductor and Internet of Things (IoT) device companies. Established in 2006 and headquartered in San Jose, California, the company delivers a comprehensive suite of services, including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, and various testing and analysis services. These services encompass product engineering, debugging, reliability testing, and failure analysis, aimed at enhancing product performance and minimizing risk. Presto Engineering also specializes in wafer fabrication, backend packaging, and supply chain solutions, supporting clients in the medical, automotive, industrial, and communication sectors. With additional offices in France, Thailand, and Taiwan, the company is positioned to facilitate rapid product development and help clients accelerate their time-to-market.

Talentsoft, established in 2007, is a leading French software company specializing in cloud-based Talent Management solutions. It offers a comprehensive suite of services, including recruitment, onboarding, performance management, and learning management, all integrated on a single platform. Talentsoft has achieved rapid growth and international success by forming strategic partnerships, maintaining high-caliber teams, and providing an attractive technology solution. With numerous awards and financial backing, the company has expanded its global presence to every continent, serving clients through its network of subsidiaries and affiliates.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

MLstate specializes in the design and development of secure communication solutions, prominently featuring its proprietary product, Peps. The company also creates the Opa framework, an advanced open-source platform for JavaScript that includes a compiler for the Opa language and a runtime JavaScript library. MLstate's offerings cater to the needs of organizations by enabling the management of emails, document collaboration, and file sharing through industrial web applications. Over the years, the company has received various accolades, including being a finalist in the GIGAOM Structure Launchpad and winning multiple awards from French governmental bodies for innovation and research.

Webinterpret, established in 2007, focuses on making international e-commerce accessible to sellers worldwide. With offices in France, Poland, China, and the USA, the company employs approximately 210 skilled e-commerce specialists who possess in-depth local market knowledge. Webinterpret operates a global marketplace platform designed to help online merchants expand their reach internationally. The platform offers a range of services, including adjustments to shipping costs, currency conversion, product categorization, accurate translations, and international stock management. These services enable online retailers and marketplace sellers to effectively grow their businesses on a global scale and enhance their online sales.

Codasystem is a French start-up specializing in digital photography technology that holds legal value. The company provides a real-time monitoring tool that enables users to capture digital photographs using their mobile phones, which can be utilized as legally admissible evidence. This innovative approach enhances the reliability of visual documentation, catering to various sectors that require verifiable photographic records.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

VoluBill S.A. specializes in real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and headquartered in Montbonnot Saint Martin, France, the company offers a range of solutions including the CHARGE-IT platform, which facilitates real-time, on-the-network convergent charging and control for data services. Its offerings encompass the CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement, as well as the CHARGE-IT Dynamic Charging Platform, designed for real-time charging and control across various payment models, such as pre-pay and post-pay. VoluBill serves a diverse clientele that includes fixed, mobile, and fixed mobile convergent operators, with additional offices located in Europe and Asia.

Glowria offers online digital video disc (DVD) rental service. Glowria was founded in 2003 is based in Paris, France.

Idylis S.A. is a software development company based in Saint-Ouen-sur-Seine, France, specializing in cloud-based solutions for enterprise management. Founded in 2008, Idylis designs and markets software that supports various functions, including audit and accounting, financial management, documentation, e-mailing, and scheduling. The company's offerings extend to commercial applications, notably in supply chain management, logistics, and inventory management. In addition to its software products, Idylis provides customer support and consulting services to enhance its clients' operational efficiency.

Numara Software France SAS provides information technology (IT) and security management solutions. It offers Precision Desktop Management, an agent-based software designed to overcome IT management complexity; Precision Patch Management, an agent-based software designed to help IT managers to address and optimize the patch deployment process; and Precision Vulnerability Management, a non-intrusive vulnerability scanner. The company also provides services, such as IT asset management, vulnerability lifecycle management, software and configuration management, patch management, applications management, system monitoring, end user support, green IT-power management, OS deployment, and compliance. It serves bank, insurance, finance, distribution, education, government, health, industry, media, services, telecom/Internet, and TRANSPORT industries Antipolis and internationally. Criston SA was formerly known as Metrix Systems SA and changed its name to Criston SA in February 2004. The company was founded in 1997 and is headquartered in Sophia Antipolis, France with additional offices in Japan France, China, and Germany. As of July 13, 2009, Numara Software France SAS operates as a subsidiary of Numara Software, Inc.

DxO, established in 2002 and headquartered in Boulogne, France, specializes in the development and sale of digital image processing products and solutions. Its primary offerings include DxO Optics Pro, a software application for image correction and enhancement, and DxO FilmPack, which gives digital images the style of conventional films. Additionally, DxO licenses its intellectual property of optics and silicon architectures for embedded still and video image processing in camera phones and digital cameras. The company also provides DxO Analyzer, an image quality evaluation solution. DxO serves a diverse range of customers, from consumer electronics manufacturers to photographers and imaging experts, distributing its products through resellers and distributors.

METabolic EXplorer, founded in 1999 and headquartered in Saint-Beauzire, France, is a biochemistry company specializing in the development of industrial fermentation processes as sustainable alternatives to petrochemical methods. The company produces functional ingredients from natural origins for use in cosmetics, nutrition-animal health products, and biomaterials synthesis. By leveraging bacterial biochemistry, METabolic EXplorer aims to create viable, long-term solutions based on renewable resources, focusing on economic performance and competitiveness. The company continually works to enhance the efficiency of microorganisms and diversify the supply of renewable raw materials to produce essential chemical compounds with wide-ranging industrial applications.

AssurOne Group is a French company based in Asnières-sur-Seine, founded in 2004, that specializes in online insurance brokerage services. It offers a range of insurance products, including life, casualty, property, and automobile insurance, accessible via the Internet and telephone. The company provides a platform that facilitates insurance contracts, registration, claims, and contract management, allowing customers to secure negotiated insurance contracts directly from providers without the need for traditional brokers. AssurOne Group serves a diverse clientele, including notable companies such as French Generali, AXA, and AG2R La Mondiale, and operates as a subsidiary of Societe Centrale Prevoir SA.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

Sefas Innovation, founded in 1991 and headquartered in Paris, France, specializes in collaborative document composition and production software. With offices in the UK and the US, the company employs over 80 staff and has been serving Fortune 500 clients for more than 15 years. Its flagship product, the Open Print software suite, is designed for sectors such as financial services, banking, insurance, utilities, telecommunications, and the public sector. Open Print enables the design, composition, and production of complex, data-driven B2C documents, allowing organizations to integrate multiple data sources for personalized communications. The software is increasingly utilized to revamp mission-critical documents to align with the latest marketing initiatives, thereby enhancing revenue opportunities. Notable clients in the UK include Nationwide, HBOS, and British Telecom, all of whom have utilized Open Print since the early 2000s.

Idylis S.A. is a software development company based in Saint-Ouen-sur-Seine, France, specializing in cloud-based solutions for enterprise management. Founded in 2008, Idylis designs and markets software that supports various functions, including audit and accounting, financial management, documentation, e-mailing, and scheduling. The company's offerings extend to commercial applications, notably in supply chain management, logistics, and inventory management. In addition to its software products, Idylis provides customer support and consulting services to enhance its clients' operational efficiency.

DSO Interactive SA designs, develops, and markets software solutions for intermediation of Internet platforms. Its products include auditing and decisional software systems for legal firms. The company also offers information technology and communication consulting services. It was formerly known as Convergence SA and changed its name to DSO Interactive in September 2004. The company was founded in 2001 and is based in Paris, France.

VoluBill S.A. specializes in real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and headquartered in Montbonnot Saint Martin, France, the company offers a range of solutions including the CHARGE-IT platform, which facilitates real-time, on-the-network convergent charging and control for data services. Its offerings encompass the CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement, as well as the CHARGE-IT Dynamic Charging Platform, designed for real-time charging and control across various payment models, such as pre-pay and post-pay. VoluBill serves a diverse clientele that includes fixed, mobile, and fixed mobile convergent operators, with additional offices located in Europe and Asia.

Founded in 1998, Netasq is an information security company based in France. It has designed and markets Unified Threat Management solutions (hardware appliances based on a derivative of FreeBSD) which combine network and application firewall with embedded anti-virus, anti-spam, VPN and content filtering functionality with an integrated real-time intrusion prevention technology: the ASQ (Active Security Qualification).

Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.

METabolic EXplorer, founded in 1999 and headquartered in Saint-Beauzire, France, is a biochemistry company specializing in the development of industrial fermentation processes as sustainable alternatives to petrochemical methods. The company produces functional ingredients from natural origins for use in cosmetics, nutrition-animal health products, and biomaterials synthesis. By leveraging bacterial biochemistry, METabolic EXplorer aims to create viable, long-term solutions based on renewable resources, focusing on economic performance and competitiveness. The company continually works to enhance the efficiency of microorganisms and diversify the supply of renewable raw materials to produce essential chemical compounds with wide-ranging industrial applications.